Therapeutic effect of pazopanib combined with radiotherapy on cervical cancer and its effect on serum levels of vascular endothelial growth factor receptor

Objective To explore the effect of pazopanib combined with radiotherapy on the level of vascular endothelial growth factor receptor(VEFGR) in patients with cervical cancer. Methods From June 2017 to June 2018, 160 patients with cervical cancer who were treated in Jinhua Municipal Central Hospital and Zhejiang Cancer Hospital were randomly divided into radiotherapy group and combination group with 80 cases in each group. Radiotherapy group received radiotherapy and combination group received pazopanib combined radiotherapy. The levels of carcinoembryonic antigen(CEA), cytokeratin 19 fragment antigen(CYFRA21-1), carbohydrate antigen 125(CA125) were detected by immunoturbidimetry; the level of serum VEFGR was detected by enzyme-linked immunosorbent assay; the level of T-lymphocyte subpopulation was measured, and the therapeutic effects and adverse reactions were compared between the two groups. Results After treatment, CEA, CYFRA21-1, CA125, CD3⁺, CD4⁺, VEFGR1, VEFGR2, VEFGR3 and the incidence of adverse reactions in the combined group were lower than those in the radiotherapy group, CD8⁺ and the total effective rate of treatment(85.00% vs. 71.25%) were higher than those in the radiotherapy group(all P<0.05). Conclusion Pazopanil combined with radiotherapy can inhibit CEA, CYFRA21-1 and CA125 levels, regulate VEFGR level, and have a significant therapeutic effect. However, the combination of pazopanib and CA125 will have an impact on the immune capacity of the body. Therefore, further analysis and study of the treatment plan should be carried out to provide help for the clinical application of the treatment plan.